Athira Pharma, Inc.
ATHA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $71 | $94 | $61 | $43 |
| G&A Expenses | $26 | $33 | $33 | $21 |
| SG&A Expenses | $26 | $33 | $33 | $21 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $4 | -$2 | $10 | -$0 |
| Operating Expenses | $101 | $125 | $104 | $64 |
| Operating Income | -$101 | -$125 | -$104 | -$64 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4 | $8 | $8 | $9 |
| Pre-Tax Income | -$97 | -$118 | -$96 | -$55 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$97 | -$118 | -$96 | -$55 |
| % Margin | – | – | – | – |
| EPS | -25.2 | -30.9 | -25.3 | -14.9 |
| % Growth | 18.4% | -22.1% | -69.8% | – |
| EPS Diluted | -25.2 | -30.9 | -25.3 | -14.9 |
| Weighted Avg Shares Out | 4 | 4 | 4 | 4 |
| Weighted Avg Shares Out Dil | 4 | 4 | 4 | 4 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $8 | $3 | $0 |
| Interest Expense | $0 | $0 | $24 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $0 |
| EBITDA | -$96 | -$126 | -$88 | -$54 |
| % Margin | – | – | – | – |